Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to osimertinib

GR Oxnard, Y Hu, KF Mileham, H Husain… - JAMA …, 2018 - jamanetwork.com
Importance Osimertinib mesylate is used globally to treatEGFR-mutant non–small cell lung
cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by theEGFRT790M …
被引用次数：640 相关文章

[引用][C] Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

GR Oxnard, Y Hu, KF Mileham, H Husain, DB Costa… - JAMA Oncology, 2018 - cir.nii.ac.jp
Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive
Lung Cancer and Acquired Resistance to Osimertinib | CiNii Research CiNii 国立情報学 …

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.

GR Oxnard, Y Hu, KF Mileham, H Husain… - JAMA …, 2018 - europepmc.org
Results Of the 143 patients evaluated, 41 (28 [68%] women) had tumor next-generation
sequencing after acquired resistance to osimertinib. Among 13 patients (32%) with …
[HTML] nih.gov

[HTML][HTML] Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to …

GR Oxnard, Y Hu, KF Mileham, H Husain… - JAMA …, 2018 - ncbi.nlm.nih.gov
Results Of the 143 patients evaluated, 41 (28 [68%] women) had tumor next-generation
sequencing after acquired resistance to osimertinib. Among 13 patients (32%) with …
[PDF] academia.edu

[PDF][PDF] Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

GR Oxnard, AB Yuebi Hu, KF Mileham, H Husain… - JAMA, 2018 - academia.edu
OBJECTIVE To understand the molecular mechanisms of acquired resistance to osimertinib
and their clinical behavior. DESIGN, SETTING, AND PARTICIPANTS Patients with advanced …

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

GR Oxnard, AB Yuebi Hu, KF Mileham, H Husain… - JAMA, 2018 - jamanetwork.com
OBJECTIVE To understand the molecular mechanisms of acquired resistance to osimertinib
and their clinical behavior. DESIGN, SETTING, AND PARTICIPANTS Patients with advanced …

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib

GR Oxnard, Y Hu, KF Mileham, H Husain… - JAMA …, 2018 - pubmed.ncbi.nlm.nih.gov
Importance Osimertinib mesylate is used globally to treat EGFR-mutant non-small cell lung
cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by the EGFR T790M …
[HTML] nih.gov

[HTML][HTML] Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib

GR Oxnard, Y Hu, KF Mileham, H Husain… - JAMA …, 2018 - ncbi.nlm.nih.gov
Objective: To understand the molecular mechanisms of acquired resistance to osimertinib
and their clinical behavior. Design, setting, and participants: Patients with advanced NSCLC …

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.

GR Oxnard, Y Hu, KF Mileham, H Husain… - JAMA …, 2018 - europepmc.org
Results Of the 143 patients evaluated, 41 (28 [68%] women) had tumor next-generation
sequencing after acquired resistance to osimertinib. Among 13 patients (32%) with …